Efficacy of sorafenib plus transcatheter arterial chemoembolization in treating hepatocellular carcinoma with portal vein tumor thrombosis: A meta-analysis
This meta-analysis aimed to evaluate the efficacy of sorafenib plus transcatheter arterial chemoembolization (TACE) in treating hepato-cellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT). Twelve randomized controlled trials published until 28th Sep 2022 were finally included. Of the to...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Sciendo
2024-09-01
|
| Series: | Acta Pharmaceutica |
| Subjects: | |
| Online Access: | https://doi.org/10.2478/acph-2024-0019 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849411950800273408 |
|---|---|
| author | Xu Li Chen Shanshan Cao Haijun Feng Zemin Yang Chao |
| author_facet | Xu Li Chen Shanshan Cao Haijun Feng Zemin Yang Chao |
| author_sort | Xu Li |
| collection | DOAJ |
| description | This meta-analysis aimed to evaluate the efficacy of sorafenib plus transcatheter arterial chemoembolization (TACE) in treating hepato-cellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT). Twelve randomized controlled trials published until 28th Sep 2022 were finally included. Of the total 1746 patients, of whom 458 received sorafenib and TACE treatment (Group S+TACE), and 1288 only underwent TACE (Group TACE), were enrolled. Outcomes including time to progression (TTP), objective response rate (ORR), disease control rate (DCR), overall survival (OS), survival rate (SR), and adverse reactions, were extracted. The OS (HR: 0.596, 95 %CI: 0.507–0.685, p < 0.001; I2 = 0.0 %) and TTP (HR: 0.379, 95 %CI: 0.205–0.553, p < 0.001; I2 = 4.5 %) in the S+TACE group were longer than those in the TACE group. The ORR (RR: 2.101, 95 %CI: 1.555–2.839, p < 0.001; I2 = 0.0 %), DCR (RR: 1.547, 95 %CI: 1.126–2.126, p = 0.007; I2 = 79.6 %) and SR (RR: 1.416, 95 %CI: 1.183-1.694, p < 0.001; I2 = 83.8 %) in the S+TACE group were higher than those in the TACE group. Compared with the TCAE group, the higher odds of HFSR, oral ulcer, and diarrhea among patients with HCC complicated by PVTT were discovered in the S+TACE group. The marginal significance was found in ascites and gastrointestinal bleeding between the two groups. Sorafenib plus TACE has good efficacy and mild adverse reactions, which may be worthy of clinical promotion. |
| format | Article |
| id | doaj-art-65171b47ae0f4d4e8fc492e3a441eec1 |
| institution | Kabale University |
| issn | 1846-9558 |
| language | English |
| publishDate | 2024-09-01 |
| publisher | Sciendo |
| record_format | Article |
| series | Acta Pharmaceutica |
| spelling | doaj-art-65171b47ae0f4d4e8fc492e3a441eec12025-08-20T03:34:36ZengSciendoActa Pharmaceutica1846-95582024-09-0174340542210.2478/acph-2024-0019Efficacy of sorafenib plus transcatheter arterial chemoembolization in treating hepatocellular carcinoma with portal vein tumor thrombosis: A meta-analysisXu Li0Chen Shanshan1Cao Haijun2Feng Zemin3Yang Chao4Department of Gastroenterology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Traditional Chinese Medicine), Hangzhou310000, ChinaDepartment of Gastroenterology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Traditional Chinese Medicine), Hangzhou310000, ChinaDepartment of Gastroenterology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Traditional Chinese Medicine), Hangzhou310000, ChinaDepartment of Gastroenterology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Traditional Chinese Medicine), Hangzhou310000, ChinaDepartment of Orthopedics 903rd Hospital of PLA Hangzhou310000, ChinaThis meta-analysis aimed to evaluate the efficacy of sorafenib plus transcatheter arterial chemoembolization (TACE) in treating hepato-cellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT). Twelve randomized controlled trials published until 28th Sep 2022 were finally included. Of the total 1746 patients, of whom 458 received sorafenib and TACE treatment (Group S+TACE), and 1288 only underwent TACE (Group TACE), were enrolled. Outcomes including time to progression (TTP), objective response rate (ORR), disease control rate (DCR), overall survival (OS), survival rate (SR), and adverse reactions, were extracted. The OS (HR: 0.596, 95 %CI: 0.507–0.685, p < 0.001; I2 = 0.0 %) and TTP (HR: 0.379, 95 %CI: 0.205–0.553, p < 0.001; I2 = 4.5 %) in the S+TACE group were longer than those in the TACE group. The ORR (RR: 2.101, 95 %CI: 1.555–2.839, p < 0.001; I2 = 0.0 %), DCR (RR: 1.547, 95 %CI: 1.126–2.126, p = 0.007; I2 = 79.6 %) and SR (RR: 1.416, 95 %CI: 1.183-1.694, p < 0.001; I2 = 83.8 %) in the S+TACE group were higher than those in the TACE group. Compared with the TCAE group, the higher odds of HFSR, oral ulcer, and diarrhea among patients with HCC complicated by PVTT were discovered in the S+TACE group. The marginal significance was found in ascites and gastrointestinal bleeding between the two groups. Sorafenib plus TACE has good efficacy and mild adverse reactions, which may be worthy of clinical promotion.https://doi.org/10.2478/acph-2024-0019hepatocellular carcinomaportal vein tumor thrombosistranscatheter arterial chemoembolizationsorafenib |
| spellingShingle | Xu Li Chen Shanshan Cao Haijun Feng Zemin Yang Chao Efficacy of sorafenib plus transcatheter arterial chemoembolization in treating hepatocellular carcinoma with portal vein tumor thrombosis: A meta-analysis Acta Pharmaceutica hepatocellular carcinoma portal vein tumor thrombosis transcatheter arterial chemoembolization sorafenib |
| title | Efficacy of sorafenib plus transcatheter arterial chemoembolization in treating hepatocellular carcinoma with portal vein tumor thrombosis: A meta-analysis |
| title_full | Efficacy of sorafenib plus transcatheter arterial chemoembolization in treating hepatocellular carcinoma with portal vein tumor thrombosis: A meta-analysis |
| title_fullStr | Efficacy of sorafenib plus transcatheter arterial chemoembolization in treating hepatocellular carcinoma with portal vein tumor thrombosis: A meta-analysis |
| title_full_unstemmed | Efficacy of sorafenib plus transcatheter arterial chemoembolization in treating hepatocellular carcinoma with portal vein tumor thrombosis: A meta-analysis |
| title_short | Efficacy of sorafenib plus transcatheter arterial chemoembolization in treating hepatocellular carcinoma with portal vein tumor thrombosis: A meta-analysis |
| title_sort | efficacy of sorafenib plus transcatheter arterial chemoembolization in treating hepatocellular carcinoma with portal vein tumor thrombosis a meta analysis |
| topic | hepatocellular carcinoma portal vein tumor thrombosis transcatheter arterial chemoembolization sorafenib |
| url | https://doi.org/10.2478/acph-2024-0019 |
| work_keys_str_mv | AT xuli efficacyofsorafenibplustranscatheterarterialchemoembolizationintreatinghepatocellularcarcinomawithportalveintumorthrombosisametaanalysis AT chenshanshan efficacyofsorafenibplustranscatheterarterialchemoembolizationintreatinghepatocellularcarcinomawithportalveintumorthrombosisametaanalysis AT caohaijun efficacyofsorafenibplustranscatheterarterialchemoembolizationintreatinghepatocellularcarcinomawithportalveintumorthrombosisametaanalysis AT fengzemin efficacyofsorafenibplustranscatheterarterialchemoembolizationintreatinghepatocellularcarcinomawithportalveintumorthrombosisametaanalysis AT yangchao efficacyofsorafenibplustranscatheterarterialchemoembolizationintreatinghepatocellularcarcinomawithportalveintumorthrombosisametaanalysis |